Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Search help
244 results
  1. Colon Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65858
    ... OS. Regorafenib Regorafenib is an inhibitor of multiple tyrosine kinase ... The safety and effectiveness of regorafenib were evaluated in a ...
  2. Rectal Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65965
    ... OS. Regorafenib Regorafenib is an inhibitor of multiple tyrosine kinase ... The safety and effectiveness of regorafenib were evaluated in a ...
  3. pdf2019NewMeShHeadingsSingleColumn.pdf 
    https://www.nlm.nih.gov/.../2019NewMeShHeadingsSingleColumn.pdf
    ... associated with X-LINKED AGAMMAGLOBULINEMIA. Tree locations: Protein-Tyrosine Kinases ... Aggressive-Driving) PI: Automobile Driving (2000-2018) Tree ...
  4. Ongoing Trials - Treatment for Restless Legs Syndrome: Future Research Needs - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK153162
    ... Cesarean Procedure: Spinal/epidural anesthesia NCT00355641 Long-Term Safety Of Ropinirole XR In Patients With RLS Drug: Ropinirole Extended Release (XR) NCT01494766 Efficacy of Tyrosine in RLS Dietary Supplement: L-Tyrosine NCT00479531 Sequential ...
  5. Appendices - Prostate cancer: diagnosis and management - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK544761
    ... receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future ... abstract Morris (2015) Efficacy analysis of ...
  6. Breast Cancer Treatment (Adult) (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65744
    ... vs. 0.2%). Neratinib Neratinib is an ... ( NCT00878709 ) trial, the safety and efficacy of 12 months of adjuvant neratinib ...
  7. pdf2019NewMeShHeadings.pdf 
    https://www.nlm.nih.gov/mesh/2019/download/2019NewMeShHeadings.pdf
    ... associated with X-LINKED AGAMMAGLOBULINEMIA. Parent Heading: Protein-Tyrosine Kinases ... Driving) Parent Heading: Automobile Driving I01.880. ...
  8. Chronic Myelogenous Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65916
    ... discomfort from a massive spleen. Targeted therapy with tyrosine kinase inhibitors Abbreviations used in this section for ... will be required before these controversies are resolved. Tyrosine kinase inhibitor-resistant CML For patients resistant to ...
  9. Childhood Brain Stem Glioma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf 
    https://www.ncbi.nlm.nih.gov/books/NBK65812
    ... concurrently with H3.3 mutations.[ 6 - 9 ] Receptor tyrosine kinase amplification: PDGFRA amplification occurs in approximately 30% ... rates of amplification observed for some other receptor tyrosine kinase genes (e.g., MET and IGF1R ).[ 13 , ...
  10. MedlinePlus Drug Information: Cabozantinib (thyroid cancer) 
    https://medlineplus.gov/druginfo/meds/a613015.html
    ... Cometriq) is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action ... Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
first · previous · 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · next · last